F
Freenome
Early cancer detection through blood-based screening tests
About Freenome
Freenome develops blood-based screening tests designed to detect cancer in its earliest, most treatable stages. The company combines multiomics technology—analyzing multiple biological signals in blood—with artificial intelligence and machine learning to create personalized cancer detection tests accessible through a standard blood draw.
Industry
Biotechnology Research
Headquarters
Brisbane, California
Company size
201-500
Founded
2014
What we do
Blood-based cancer screeningMultiomics technologyMachine learning and AI for disease detectionEarly cancer detection
Interested in Freenome?
Join our talent pool to be considered for future opportunities.